Annotation Detail
Information
- Associated Genes
- FCGR3A
- Associated Variants
-
FCGR3A p.Phe176Val (p.F176V)
(
ENST00000367967.8,
ENST00000436743.7,
ENST00000699395.1,
ENST00000699397.1,
ENST00000699399.1,
ENST00000699401.1,
ENST00000699396.1,
ENST00000426740.8,
ENST00000699400.1,
ENST00000443193.6,
ENST00000699398.1 )
FCGR3A p.Phe176Val (p.F176V) ( ENST00000367967.8, ENST00000426740.8, ENST00000436743.7, ENST00000443193.6, ENST00000699395.1, ENST00000699396.1, ENST00000699397.1, ENST00000699398.1, ENST00000699399.1, ENST00000699400.1, ENST00000699401.1 ) - Associated Disease
- breast cancer
- Source Database
- CIViC Evidence
- Description
- A total of 57 women with HER2-positive metastatic breast cancer were analyzed after taxane plus trastuzumab chemotherapy. FCGR3A V158F carriers did not have a significantly different response rate, progression-free survival, or overall survival.
- Variant Origin
- Common Germline
- Variant Origin
- Common Germline
- Evidence URL
- https://civic.genome.wustl.edu/links/evidence_items/1085
- Gene URL
- https://civic.genome.wustl.edu/links/genes/1844
- Variant URL
- https://civic.genome.wustl.edu/links/variants/457
- Rating
- 3
- Evidence Type
- Prognostic
- Disease
- Breast Cancer
- Evidence Direction
- Does Not Support
- Evidence Level
- B
- Clinical Significance
- N/A
- Pubmed
- 22906996
Drugs